All are true about Guillain-Barre syndrome except:

Explanation

## Correct Answer: B. Descending paralysis is seen Guillain-Barré syndrome (GBS) is characterized by **ascending paralysis**, not descending paralysis. The hallmark clinical feature is onset of weakness in the lower extremities that progressively ascends to involve proximal muscles, trunk, and eventually cranial nerves and respiratory muscles in severe cases. This ascending pattern is pathognomonic and distinguishes GBS from other paralytic conditions like myasthenia gravis or botulism (which show descending paralysis). The ascending pattern reflects the anatomical distribution of demyelination along peripheral nerves, typically starting distally in the lower limbs. In Indian clinical practice, recognition of this ascending pattern is critical for early diagnosis and ICU admission planning, as respiratory failure may develop within 24–72 hours of symptom onset. The question tests whether students can differentiate GBS's characteristic ascending pattern from descending paralysis seen in conditions like botulism or myasthenia gravis. ## Why the other options are wrong **A. Plasmapheresis is a treatment method** — This is correct and is a standard treatment for GBS. Plasmapheresis removes circulating autoantibodies and immune complexes, reducing demyelination. It is recommended within 2 weeks of symptom onset and is particularly effective in India where IVIG may be less accessible in resource-limited settings. This is a true statement about GBS management. **C. Inflammatory condition** — This is correct. GBS is an acute inflammatory demyelinating polyradiculoneuropathy (AIDP). The pathophysiology involves autoimmune attack on myelin sheaths of peripheral nerves, with infiltration of T cells and macrophages. CSF shows elevated protein with normal cell count (albuminocytologic dissociation), confirming the inflammatory nature. This is a true statement. **D. Demyelinating disorder** — This is correct. GBS is the prototype acute demyelinating peripheral neuropathy. Nerve conduction studies show demyelinating features (slowed conduction velocity, prolonged distal latencies, conduction blocks). The primary pathology is demyelination of peripheral nerves, though axonal variants (AMAN, AMSAN) also exist. This is a true statement about GBS pathology. ## High-Yield Facts - **Ascending paralysis** is the pathognomonic pattern in GBS, starting distally in lower limbs and progressing upward—opposite of descending paralysis in botulism or myasthenia gravis. - **Albuminocytologic dissociation** (elevated CSF protein with normal cell count <10/μL) is the classic CSF finding in GBS. - **Plasmapheresis and IVIG** are the two main immunotherapies; plasmapheresis is preferred within 2 weeks of onset in Indian guidelines. - **Respiratory failure** occurs in 25–30% of GBS cases and is the leading cause of mortality; ICU monitoring is essential. - **Demyelinating features** on NCS include slowed conduction velocity, prolonged distal latencies, and conduction blocks across multiple nerves. ## Mnemonics **GBS vs Botulism (Paralysis Direction)** **GBS = Going UP** (ascending paralysis from feet to head). **Botulism = Blinking DOWN** (descending from eyes/face downward). Use this to remember GBS always ascends. **GBS Diagnosis: ACID** **A**scending paralysis, **C**SF albuminocytologic dissociation, **I**nflammatory demyelinating, **D**emyelination on NCS. Quick checklist for GBS features. ## NBE Trap NBE pairs "paralysis" with GBS to trap students who confuse the direction of progression. Many students recall that GBS causes paralysis but forget it is ascending, not descending, leading them to incorrectly validate option B as true. ## Clinical Pearl In Indian emergency departments, a patient presenting with acute lower limb weakness that progresses upward over hours to days with preserved sensation and areflexia should trigger immediate GBS suspicion and ICU referral. Early plasmapheresis within the first 2 weeks can significantly reduce duration of mechanical ventilation and improve functional recovery. _Reference: Harrison Ch. 379 (Guillain-Barré Syndrome); Robbins Ch. 27 (Peripheral Neuropathies)_